Understanding Biologically Effective Dose in Radiation Therapy

Radiation therapy is delivered in an enormous variety of ways: a single large fraction, many small daily fractions, twice-daily treatments, or high-dose ablative stereotactic regimens. To compare the biological impact of these radically different schedules, clinicians and radiobiologists need a common currency that accounts not just for the total dose delivered, but for how that dose is divided over time. The Biologically Effective Dose (BED) is that currency.

BED is a calculated quantity derived from the linear-quadratic (LQ) model of cell killing that allows any fractionation schedule to be expressed in terms of its expected biological effect on a given tissue. Rather than comparing schedules by their total physical dose alone, BED incorporates the size of each fraction, the total number of fractions, and the radiosensitivity characteristics of the tissue being irradiated. It is an indispensable tool in modern radiation oncology for schedule comparison, treatment planning, re-irradiation decisions, and the safe implementation of hypofractionated and stereotactic ablative radiotherapy (SABR/SBRT).

The Linear-Quadratic Model: Biological Foundation

The BED formula is derived from the linear-quadratic (LQ) model of radiation-induced cell killing, one of the most extensively validated models in radiobiology. The LQ model describes how the fraction of cells surviving a given radiation dose depends on two types of DNA damage: lethal single-hit events (the linear, or alpha, component) and sub-lethal damage that accumulates from two separate ionization events (the quadratic, or beta, component).

When a cell is irradiated, ionizing radiation can kill it through a single double-strand DNA break that is irreparable (proportional to dose, described by the alpha term) or through two sub-lethal lesions that interact to produce a lethal event (proportional to the square of the dose, described by the beta term). This gives the surviving fraction (SF) after a dose d:

SF = e^{−(αd + βd²)}

For a course of n fractions each of dose d, the log of the surviving fraction is:

log SF = −n (αd + βd²) = −α × BED

This derivation forms the mathematical basis for BED and explains why the formula has the structure it does.

The BED Formula

The Biologically Effective Dose is calculated as:

BED = D × (1 + d / (α/β))

Where:

• D = Total physical dose delivered (in Gray, Gy), equal to n × d
• d = Dose per fraction (in Gy)
• n = Number of fractions
• α/β = The alpha/beta ratio of the tissue of interest (in Gy)

The formula can equivalently be written as:

BED = n × d × (1 + d / (α/β))

The term in parentheses, (1 + d / (α/β)), is called the relative effectiveness (RE) per fraction. It captures how much more or less biologically potent each fraction is compared to a reference condition, based on the fraction size and the tissue sensitivity. BED is expressed in units of Gray (Gy), but these are notional Gray values representing biological effect, not physical dose, and they are tissue-specific. A BED of 80 Gy for a tumor with α/β = 10 Gy is not directly comparable to a BED of 80 Gy for late-responding normal tissue with α/β = 3 Gy.

The Alpha/Beta Ratio: The Key Parameter

The α/β ratio is the most important tissue-specific parameter in the BED calculation. It represents the dose at which the linear (alpha) and quadratic (beta) components of cell killing contribute equally. Numerically, it is the dose per fraction at which the single-hit killing equals the two-hit killing.

Tissues with a high α/β ratio (typically around 10 Gy) respond predominantly through the linear component. They are relatively insensitive to fraction size, meaning that changing from 2 Gy per fraction to 3 Gy per fraction produces a proportionally smaller increase in biological effect. Rapidly proliferating tissues, including most tumors and acutely responding normal tissues (mucosa, skin), tend to have high α/β ratios.

Tissues with a low α/β ratio (typically around 1–3 Gy) respond predominantly through the quadratic component and are highly sensitive to fraction size. Small increases in fraction size produce disproportionately large increases in biological effect. Late-responding normal tissues (spinal cord, brain, kidney, lung parenchyma) typically have low α/β ratios, which is why they are particularly susceptible to injury from large fractions.

Commonly Used α/β Values

These values are averages derived from clinical and experimental data. Individual variation exists, and some values (particularly for uncommon endpoints or rare tumors) carry substantial uncertainty. For clinical decision-making, especially in re-irradiation settings, the clinician should reference the most current literature for tissue-specific α/β values.

Fractionation Sensitivity and the Therapeutic Window

The central insight that underpins the clinical utility of BED is the concept of differential fractionation sensitivity. Because most tumors have a higher α/β ratio than late-responding normal tissues, they respond differently to changes in fraction size. This differential sensitivity creates a therapeutic window that can be exploited to improve the therapeutic ratio.

Conventional Fractionation

Standard or conventional fractionation uses 1.8 to 2.0 Gy per fraction, delivered once daily, five days per week. This schedule was historically established empirically and later understood to exploit the fractionation sensitivity differential. At 2 Gy per fraction, the relative effectiveness for a late-responding normal tissue (low α/β) is substantially higher than it would be if all dose were given in a single fraction, meaning that conventional fractionation progressively spares late-responding tissue relative to tumor. Over many fractions, this accumulates into a meaningful therapeutic advantage.

Hyperfractionation

Hyperfractionation uses smaller fractions (<1.8 Gy) delivered more than once daily, with the total dose increased compared to conventional fractionation. By reducing fraction size, the quadratic component of late-normal-tissue injury is further reduced, theoretically widening the therapeutic window. The EORTC 22791 trial demonstrated a survival benefit for hyperfractionated radiotherapy in head and neck cancer, providing clinical proof of concept. However, the practical constraints of twice-daily treatment have limited widespread adoption.

Hypofractionation

Hypofractionation uses larger fractions (>2 Gy) and fewer total fractions, often delivering a biologically equivalent or superior dose to the tumor in a shorter overall treatment time. This approach is most advantageous for tumors with low α/β ratios (such as prostate and breast cancer), where the tumor is as sensitive to fraction size as the surrounding late-responding normal tissues. Randomized trials in breast cancer (START trials) and prostate cancer (CHHiP, PROFIT trials) have demonstrated equivalence or superiority of moderate hypofractionation compared to conventional fractionation, and hypofractionated schedules are now standard of care for these disease sites.

Stereotactic Ablative Radiotherapy (SABR/SBRT)

Stereotactic body radiotherapy (SBRT), also known as stereotactic ablative radiotherapy (SABR), delivers very large doses per fraction (typically 6–20 Gy or more) in a small number of fractions (1–5), with extreme precision to small, well-defined targets. At these very large fraction sizes, the LQ model predicts extremely high BED values, often >100 Gy. However, at doses per fraction above approximately 6–10 Gy, there is ongoing debate about whether the LQ model continues to accurately predict biological effect, as additional mechanisms of cell killing (such as vascular damage and immune stimulation) may contribute at ablative doses.

Equivalent Dose in 2 Gy Fractions (EQD2)

While BED is excellent for comparing schedules mathematically, it is not expressed in units that correspond to any real-world treatment delivered in standard practice. The Equivalent Dose in 2 Gy Fractions (EQD2) addresses this by converting a BED to the total dose that would be required using conventional 2 Gy fractions to achieve the same biological effect in the same tissue.

EQD2 = BED / (1 + 2 / (α/β)) = D × (d + α/β) / (2 + α/β)

EQD2 is particularly useful in clinical communication and in comparing published trial data. When a radiation oncologist states that a hypofractionated prostate schedule of 60 Gy in 20 fractions is equivalent to 78 Gy in 39 fractions, they are using EQD2 (calculated with the prostate tumor α/β of 1.5 Gy) to make that comparison. The EQD2 framework allows results from trials using different fractionation schedules to be placed on a common scale and directly compared.

It is critical to always state which α/β ratio was used when reporting or interpreting EQD2, since the same physical schedule will yield different EQD2 values depending on the tissue of interest. A schedule that is highly favorable in terms of EQD2 for tumor control may be unfavorable in terms of EQD2 for normal tissue toxicity if the two tissues have different α/β ratios.

Clinical Applications of BED and EQD2

Comparing Fractionation Schedules

The most fundamental use of BED is to determine whether two different fractionation schedules are biologically equivalent. Consider a head and neck oncologist choosing between 70 Gy in 35 fractions (conventional) and 66 Gy in 30 fractions (mild hypofractionation). By calculating BED for each schedule using the tumor α/β of 10 Gy, the clinician can determine whether the altered schedule is likely to produce similar tumor control. They can simultaneously calculate BED for late-responding normal tissues using α/β of 3 Gy to check whether the altered schedule changes the predicted late toxicity profile.

Breast Cancer Hypofractionation

The biological rationale for hypofractionated whole-breast irradiation rests on the relatively low α/β ratio of breast cancer (estimated at 3–4 Gy), which is similar to the α/β of the late-responding normal tissues in the breast and chest wall. When tumor and normal tissue have similar α/β ratios, changing fraction size does not produce the same differential sparing effect as it would in a high α/β tumor. BED calculations show that schedules such as 40 Gy in 15 fractions (UK standard) or 42.5 Gy in 16 fractions (Canadian standard) have BED values for tumor control similar to 50 Gy in 25 fractions, with comparable or improved normal tissue BED profiles. This radiobiological equivalence was confirmed by randomized trial data.

Prostate Cancer Hypofractionation and SBRT

Prostate cancer has one of the lowest α/β ratios among common solid tumors, with estimates typically ranging from 1.5 to 3 Gy. This unusually low value (lower than many late-responding normal tissues) means that hypofractionation actually provides a therapeutic advantage: larger fractions kill prostate cancer cells proportionally more efficiently while relatively sparing normal tissue. BED calculations using α/β = 1.5 Gy predict that schedules such as 60 Gy in 20 fractions (3 Gy per fraction) are more effective than conventional 78 Gy in 39 fractions, a prediction validated by clinical trial data. For prostate SBRT (for example, 36.25 Gy in 5 fractions), BED values in excess of 150 Gy are calculated using the low α/β of prostate cancer, reflecting the high potency of ablative fraction sizes for this disease.

Lung SBRT

Lung SBRT for early-stage non-small cell lung cancer (NSCLC) is one of the most established SBRT applications. Common schedules include 54 Gy in 3 fractions (18 Gy per fraction) for peripheral tumors and 50 Gy in 5 fractions (10 Gy per fraction) or 60 Gy in 8 fractions (7.5 Gy per fraction) for central or ultra-central lesions where higher fraction sizes carry greater risk of toxicity. BED calculations (using α/β = 10 Gy for tumor) show that these schedules produce tumor BED values well above 100 Gy, which is the threshold empirically associated with high local control rates in lung SBRT. Simultaneously, normal tissue BED constraints are calculated for the spinal cord, esophagus, heart, and bronchial tree to verify safety.

Liver and Abdominal SBRT

SBRT is increasingly used for liver metastases, hepatocellular carcinoma, pancreatic cancer, renal cell carcinoma, and adrenal metastases. BED calculations are used to select schedules that achieve sufficient tumor BED while respecting the tolerance of critical adjacent structures. The liver parenchyma, bile ducts, duodenum, and stomach are dose-limiting structures with low fractionation tolerance at high doses per fraction. BED and EQD2 calculations are used alongside constraint tables to navigate these competing risks.

Re-irradiation

Re-irradiation is one of the most demanding applications of BED and EQD2 calculations. When a patient previously treated with radiotherapy develops a local recurrence or a second primary in or adjacent to a previously irradiated field, the clinician must estimate the residual normal tissue tolerance. This requires knowing the EQD2 of the prior course (calculated from the original schedule), the time elapsed since prior treatment (during which some repair and repopulation occurs), and the EQD2 of the proposed re-treatment course. The sum of EQD2 values, corrected for time-dependent recovery, is compared to published tolerance limits for each critical structure. BED-based re-irradiation calculations are most commonly applied to the spinal cord, brain, head and neck normal tissues, and the chest wall.

Brachytherapy

Brachytherapy, in which radioactive sources are placed within or immediately adjacent to a tumor, delivers radiation in a fundamentally different spatial and temporal pattern from external beam radiotherapy. High-dose-rate (HDR) brachytherapy delivers discrete fractions, each of which can be treated as a standard fraction in the LQ model. Low-dose-rate (LDR) brachytherapy delivers dose continuously over hours to days, and the LQ model requires a correction factor for the continuous dose rate (the Lea-Catcheside factor, g(T)). The BED formula for LDR brachytherapy is:

BED_LDR = D × (1 + g(T) × D_dot / (α/β))

Where D_dot is the dose rate and g(T) corrects for the repair that occurs during the continuous exposure. In practice, most clinical LDR brachytherapy BED calculations use tabulated or software-calculated values for g(T) based on the repair half-time of the tissue and the treatment duration. For HDR brachytherapy, the standard BED formula applies directly to each fraction and the total BED is the sum across all fractions.

Worked Clinical Examples

Example 1: Conventional vs. Hypofractionated Prostate Radiotherapy

Schedule A (conventional): 78 Gy in 39 fractions (2 Gy/fraction)
Schedule B (hypofractionated): 60 Gy in 20 fractions (3 Gy/fraction)

Using α/β = 1.5 Gy for prostate tumor:

• BED_A = 78 × (1 + 2/1.5) = 78 × 2.33 = 181.7 Gy
• BED_B = 60 × (1 + 3/1.5) = 60 × 3.00 = 180.0 Gy

Using α/β = 3 Gy for late-responding normal tissue (rectum, bladder):

• BED_A = 78 × (1 + 2/3) = 78 × 1.67 = 130.0 Gy
• BED_B = 60 × (1 + 3/3) = 60 × 2.00 = 120.0 Gy

The two schedules deliver near-identical tumor BED (181.7 vs. 180.0 Gy), but Schedule B delivers a lower normal tissue BED (120.0 vs. 130.0 Gy), predicting similar tumor control with potentially reduced late toxicity. This is the radiobiological basis for the hypofractionation advantage in prostate cancer.

Example 2: Lung SBRT BED Calculation

Schedule: 54 Gy in 3 fractions (18 Gy/fraction) for a peripheral T1 NSCLC

Using α/β = 10 Gy for lung tumor:

• BED = 54 × (1 + 18/10) = 54 × 2.80 = 151.2 Gy

Using α/β = 3 Gy for late-responding lung parenchyma:

• BED = 54 × (1 + 18/3) = 54 × 7.00 = 378.0 Gy

The tumor BED of 151.2 Gy is well above the 100 Gy threshold associated with high local control in lung SBRT. The very high normal tissue BED (378 Gy) reflects the extreme sensitivity of lung parenchyma to large fractions and emphasizes why precise targeting and careful normal tissue dosimetry are essential in SBRT.

Example 3: EQD2 Conversion for Schedule Comparison

A radiation oncologist wants to compare two head and neck schedules:

• Schedule A: 70 Gy in 35 fractions (2 Gy/fraction, conventional)
• Schedule B: 66 Gy in 30 fractions (2.2 Gy/fraction, mild hypofractionation)

EQD2 for tumor (α/β = 10 Gy):

• EQD2_A = 70 × (2 + 10) / (2 + 10) = 70.0 Gy
• EQD2_B = 66 × (2.2 + 10) / (2 + 10) = 66 × 12.2/12 = 67.1 Gy

EQD2 for late-responding normal tissue (α/β = 3 Gy):

• EQD2_A = 70 × (2 + 3) / (2 + 3) = 70.0 Gy
• EQD2_B = 66 × (2.2 + 3) / (2 + 3) = 66 × 5.2/5 = 68.6 Gy

Schedule B delivers slightly less tumor EQD2 (67.1 vs. 70.0 Gy) but also a slightly lower normal tissue EQD2 (68.6 vs. 70.0 Gy). The schedule is modestly inferior for tumor control but may offer a small normal tissue advantage while also shortening treatment by one week.

Example 4: BED in Breast Hypofractionation

Schedule A (conventional): 50 Gy in 25 fractions (2 Gy/fraction)
Schedule B (hypofractionated): 40 Gy in 15 fractions (2.67 Gy/fraction)

Using α/β = 4 Gy for breast tumor:

• BED_A = 50 × (1 + 2/4) = 50 × 1.50 = 75.0 Gy
• BED_B = 40 × (1 + 2.67/4) = 40 × 1.67 = 66.8 Gy

Using α/β = 3 Gy for late-responding breast tissue:

• BED_A = 50 × (1 + 2/3) = 50 × 1.67 = 83.5 Gy
• BED_B = 40 × (1 + 2.67/3) = 40 × 1.89 = 75.6 Gy

Both tumor BED and normal tissue BED are somewhat lower for Schedule B, which is consistent with clinical trial results showing non-inferior local control and comparable or reduced late toxicity with hypofractionated breast radiotherapy. The BED model alone would predict slight inferiority of Schedule B, but clinical data have not shown this difference to be significant, illustrating the limitations of BED as a sole decision-making tool.

BED and Overall Treatment Time: The Proliferation Correction

The basic BED formula does not account for tumor cell repopulation during treatment. In rapidly proliferating tumors, particularly squamous cell carcinomas of the head and neck, cervix, and lung, tumor cells continue to divide during a course of radiotherapy. If the overall treatment time is prolonged, whether by treatment breaks, weekends, or a deliberately slower schedule, surviving tumor cells repopulate and partially counteract the cytotoxic effect of radiation.

A proliferation-corrected BED can be calculated by subtracting a term representing the log cell kill recovered through repopulation:

BED_corrected = D × (1 + d / (α/β)) − (ln2 / T_pot) × (T − T_kick) / α

Where T_pot is the potential doubling time of the tumor, T is the overall treatment time, T_kick is the time at which accelerated repopulation begins (typically estimated at 3–4 weeks for head and neck squamous cell carcinomas), and α is the linear radiosensitivity parameter. In practice, the proliferation correction is most relevant for head and neck squamous cell carcinomas, where the impact of treatment prolongation on local control is well established. Treatment breaks of even a few days in a head and neck course are estimated to reduce local control probability by approximately 1–2% per additional day, based on BED-derived and clinical data.

The proliferation term is less relevant for slowly proliferating tumors (prostate, breast, low-grade glioma) where T_pot is long and the kick-off time may exceed the overall treatment duration. In these cases, the basic BED formula without the proliferation correction is sufficient for most clinical planning purposes.

Normal Tissue Complication Probability and BED

BED is closely related to, but distinct from, Normal Tissue Complication Probability (NTCP) modeling. NTCP models use BED-equivalent quantities as inputs to sigmoidal dose-response curves to estimate the probability of a specific complication in a given normal tissue. Parameters such as the TD50 (dose that produces complications in 50% of patients) and the steepness parameter (gamma50 or k) are derived from clinical datasets and incorporated into NTCP models such as the Lyman-Kutcher-Burman (LKB) model.

In modern radiotherapy planning, BED and EQD2 calculations are often performed automatically by treatment planning systems (TPS) as part of plan evaluation. Constraints derived from published NTCP data are specified in EQD2 terms, and the planning system evaluates whether the plan meets these constraints. Manual BED calculation, as provided by online calculators, remains essential for quick schedule comparisons, re-irradiation planning, and situations where sophisticated TPS-integrated calculations are not available.

Important Limitations of the BED Model

• LQ model validity at high doses per fraction: The LQ model was developed and validated for fraction sizes in the conventional range (1–5 Gy). At very large fraction sizes used in SBRT (>6–10 Gy per fraction), the model may overestimate cell killing because it does not account for all mechanisms of radiation-induced death operating at high doses, nor for the potential radioprotective effect of hypoxia reoxygenation dynamics at large single fractions. Modified LQ models and the universal survival curve (USC) model have been proposed to address this limitation, but none has been universally adopted.
• Uncertainty in α/β values: Published α/β values carry significant uncertainty, particularly for uncommon tumors, rare complications, and individual patient variation. For prostate cancer, estimates of α/β range from 1.1 to 4.0 Gy across different studies, and the choice of value substantially affects BED and EQD2 calculations.
• Homogeneous dose assumption: The standard BED formula assumes uniform dose delivery to the target volume. In modern conformal and intensity-modulated radiotherapy (IMRT), dose is highly inhomogeneous within the target and surrounding normal tissues. Volume effects (the bath-and-shower effect) mean that the biological impact of a given BED depends on how much of an organ receives that dose. BED calculations based on mean dose or point doses do not capture this volume effect.
• No accounting for spatial dose distribution: BED is a point or volume-average quantity. It does not describe the spatial dose distribution within a tissue, which can be critical for understanding the risk of complications in serially organized tissues (such as the spinal cord, where a single high-dose hotspot can cause myelopathy regardless of the mean dose to the cord).
• Tumor heterogeneity: Real tumors contain subpopulations of cells with different radiosensitivities, hypoxic fractions, and proliferation rates. The LQ model treats the tumor as a homogeneous population, which is a simplification. Hypoxic tumor cells are substantially more radioresistant and may have different α/β characteristics than well-oxygenated cells.
• No modeling of immune effects: High-dose SBRT is now recognized to have immunomodulatory effects, including the abscopal effect (regression of non-irradiated metastases following focal irradiation). These effects are not captured by the LQ model and may contribute meaningfully to the clinical outcomes seen with SBRT schedules at doses that the LQ model predicts to be extremely toxic to normal tissues.
• Repair kinetics not captured in standard formula: The standard BED formula assumes complete repair between fractions (i.e., adequate interfraction interval, typically at least 6 hours). When fractions are delivered less than 6 hours apart (as in some twice-daily schedules), incomplete repair amplifies the effective biological dose. The incomplete repair correction factor (the Lea-Catcheside factor) should be applied in these situations.
• Not a substitute for clinical judgment: BED and EQD2 are radiobiological tools that inform, but do not replace, clinical decision-making. They should be used alongside patient-specific factors, performance status, comorbidities, tumor characteristics, and published clinical outcome data.

Practical Guidance for Using the BED Calculator

Selecting the Correct α/β Ratio

The choice of α/β ratio is the most consequential decision in a BED calculation. Always use the α/β ratio appropriate to the specific tissue and endpoint you are evaluating. If you are evaluating tumor control, use the α/β for the specific tumor type. If you are evaluating a normal tissue constraint, use the α/β for that specific normal tissue and the specific complication endpoint of concern (acute vs. late, specific organ).

Using the Correct Total Dose and Fraction Size

Ensure that D (total dose) equals n (number of fractions) multiplied by d (dose per fraction). Small errors in these inputs produce proportionally large errors in BED, particularly at high doses per fraction where the quadratic term dominates. When converting from a dose prescription given in total dose and number of fractions, always calculate d explicitly rather than relying on rounded values.

Interpreting BED Values

BED values are only meaningful in comparison to a reference. A calculated BED of 84 Gy for a tumor has meaning only when compared to the BED of an established standard-of-care schedule for the same tumor type. It does not have an absolute interpretation (unlike physical dose in Gray). Always compare BED or EQD2 values calculated with the same α/β ratio to make valid schedule comparisons.

Using EQD2 for Clinical Communication

When communicating with colleagues, reporting to tumor boards, or comparing with published trial data, EQD2 is usually more informative than BED because it is expressed in units that correspond to a familiar, real-world treatment (standard 2 Gy fractionation). Most published dose constraints for normal tissues are expressed in EQD2 or assume conventional 2 Gy per fraction, making EQD2 the natural unit for constraint evaluation.

Documenting Assumptions

Any BED or EQD2 calculation reported in a clinical note, re-irradiation plan, or research document should clearly state the α/β ratio used and the source or basis for that value. Given the uncertainty in α/β ratios, sensitivity analyses using the plausible range of α/β values are advisable for high-stakes decisions such as re-irradiation near the spinal cord.